Chairman of the Board
Mr. Macdonald joined the board in November 2014 and became Chairman in June 2015. Mr. Macdonald served as the President and Chief Executive Officer and member of the board of directors of Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH) from January 2008 to August 2019. From August 2003 until January 2008, Mr. Macdonald served as Executive Vice President of Operations of Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company. From 1981 to 2003 he served in various positions at Merck & Co., Inc. (NYSE: MRK), most recently serving as the Vice President for Anti-Infective and Hospital Products. Mr. Macdonald received an Honors Degree in biochemistry from Dundee University in Dundee, Scotland.
Mr. Anido has served as Chairman and Chief Executive Officer (CEO) of Zynerba Pharmaceuticals since October 2014. Mr. Anido has more than 30 years of executive, operational and commercial leadership experience in the biopharmaceutical industry. Prior to Zynerba, Mr. Anido served as CEO of two publicly traded companies. Most recently, he was the CEO of NuPathe Inc., which was acquired by Teva Pharmaceuticals in February 2014. At NuPathe, he led the company through FDA approval of its lead product, Zecuity®, the first transdermal patch for migraine, to pre-launch before the company's acquisition by Teva. He also served as President and CEO of Auxilium Pharmaceuticals, a specialty pharmaceutical company acquired by Endo Pharmaceuticals, Inc. in January 2015. Under Mr. Anido's leadership at Auxilium, sales grew from $42 million in 2005 to more than $260 million in 2011. Prior to Auxilium, Mr. Anido served as Executive Vice President, Sales and Marketing, at MedImmune, where Synagis, an anti-viral for RSV, became a blockbuster product, and prior to that, in senior sales and marketing positions at GlaxoWellcome and Lederle Laboratories. At Lederle, he was Vice President, Anti-Infectives, responsible for the commercialization of the anti-bacterials, Suprax and Zosyn. He is currently a member of the Board of Directors of AURIS Medical Holding AG and Life Science PA, and he was a member of the Board of Directors of Adolor Corporation until it was sold to Cubist Pharmaceuticals in December 2011. Mr. Anido earned a BS in Pharmacy and an MBA from West Virginia University.
Steven C. Gilman, Ph.D.
Dr. Gilman joined the board in February 2015. Prior to his retirement in April 2019, Dr. Gilman served as the Chairman and Chief Executive Officer of ContraFect since May 2015. He also served as the Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals until its acquisition by Merck & Co. in January 2015. Prior to joining Cubist, Dr. Gilman served as President and CEO of ActivBiotics from March 2004 to June 2006 and Chairman and CEO from July 2006 to October 2007. Previously, Dr. Gilman worked at Millennium Pharmaceuticals, Inc., from October 2000 to March 2004 where he held a number of senior leadership roles including Vice President and General Manager, Inflammation. Prior to Millennium, he was Group Director at Pfizer Global Research and Development. He has also held scientific, business and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School and Connecticut College. Dr. Gilman currently serves on the board of directors of ContraFect Corporation (Nasdaq: CFRX), Akebia Therapeutics, Inc. (Nasdaq: AKBA), and Vericel Corporation (Nasdaq: VCEL). He is a past member of the board of directors of Momenta Pharmaceuticals (Nasdaq MNTA), the Massachusetts Biotechnology Association, the Northeastern University Drug Discovery Advisory Board and the Penn State University Biotechnology Advisory Board. Dr. Gilman received his Ph.D. and M.S. degrees in Microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinical and Research Foundation and received a B.A. in Microbiology from Miami University of Ohio.
Ann F. Hanham, Ph.D.
Dr. Hanham has served as a member of the board of directors since December 2008. Prior to becoming a Founding Partner and Managing Director of BAR Capital Management in December 2013, she was a General Partner with Burrill & Company, a life sciences venture capital firm, from 2000 to 2013. From 1998 to 2000, Dr. Hanham was a co-founder and Vice President of Clinical & Regulatory Affairs at InterMune, Inc. (Nasdaq: ITMN). From 1995 to 1998, she served as the Senior Director for Oncology Product Development at Otsuka Pharmaceutical, Inc. and from 1991 to 1995 as the Medical Director for Celtrix Pharmaceuticals Inc. From 1988 to 1991, Dr. Hanham worked for Becton Dickinson and Company (Nasdaq: BDX) in both regulatory and clinical affairs for the monoclonal antibody program, and from 1984 to 1988 as a regulatory toxicologist with the Health Protection Branch of Health and Welfare Canada. Dr. Hanham currently serves on the board of HTC Molecular Diagnostics Inc. (Nasdaq: HTGM). Dr. Hanham holds a Ph.D. from the University of British Columbia, an MSc from Simon Fraser University, and a BSc from the University of Toronto. She was also Board Certified in Toxicology in 1986.
Mr. Hastings joined the board in September 2015. He currently serves as the Chief Financial Officer at Arbutus Biopharma Corp. (Nasdaq: ABUS). Prior to joining Arbutus in June 2018, Mr. Hastings served as the Senior Vice President and Chief Financial Officer of Unilife Corporation from February 2015 to June 2017. From October 2003 to October 2014, he served as Executive Vice President and Chief Financial Officer at Incyte Corporation (Nasdaq: INCY). From February 2000 to September 2003, Mr. Hastings served as Vice President, Chief Financial Officer and Treasurer of ArQule, Inc. (Nasdaq: ARQL). Prior to his employment with ArQule and from June 1997 to February 2000, Mr. Hastings was Vice President and Corporate Controller at Genzyme, Inc. (Nasdaq: GENZ), where he was responsible for the management of the finance department. Prior to his employment with Genzyme and from May 1994 to June 1997, Mr. Hastings was the Director of Finance at Sepracor, Inc., where he was primarily responsible for Sepracor's internal and external reporting. He currently serves as a member of the board of directors of VBL Therapeutics (Nasdaq: VBLT) and Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX). Mr. Hastings received his B.A. in Economics at the University of Vermont.
During his career at Vertex Pharmaceuticals Incorporated, Mr. Tinmouth led or managed teams leading the company's business transactions, yielding multiple clinical candidates and upfront cash of nearly $1B. Prior to joining Vertex in 2002, Mr. Tinmouth was a Senior Manager in the Boston office of Bain & Company, where he advised both Fortune 50 pharmaceutical companies and smaller biotechnology companies on growth strategies. Mr. Tinmouth has served as a mentor and advisor to biotech start-ups through both the Harvard Innovation Lab (Harvard iLab) and the Canadian Technology Accelerator. Early in his career, Mr. Tinmouth was a design engineer at Bombardier Aerospace, where he was a member of the flight test team for the Canadair Regional Jet. He holds a Master's Degree in Business Administration from Harvard Business School and a Bachelor's Degree with Honors in Mechanical Engineering from Queen's University in Canada.
Marco Taglietti, M.D.
President and Chief Executive Officer
Dr. Taglietti has served as Chief Executive Officer of SCYNEXIS since April 2015 and became President of the Company in September 2015. He has been a member of the board since November 2014. He served as Executive Vice President, Research and Development and Chief Medical Officer of Forest Laboratories, Inc. and as President of the Forest Research Institute until its acquisition by Actavis in 2014. Prior to joining Forest Laboratories in 2007, Dr. Taglietti held the position of Senior Vice President, Head of Global Research and Development, at Stiefel Laboratories, Inc., a GSK company, for three years. He joined Stiefel Laboratories after 12 years at Schering-Plough Corporation, where he last held the position of Vice President, Worldwide Clinical Research for Anti-Infectives, Oncology, CNS, Endocrinology and Dermatology. Dr. Taglietti began his pharmaceutical career at Marion Merrell Dow Research Institute. Over the course of his career, he has brought to market 35 different products in the U.S. and internationally. Dr. Taglietti currently serves on the Board of Directors of BioNJ, Inc. and Aquestive Therapeutics, Inc. (Nasdaq: AQST). He received his medical degree and board certifications from the University of Pavia in Italy.